The link between IL-1β expression and gastric cancer progression in humans and murine models, has resulted in IL-1 receptor blockade being suggested as a novel therapeutic target in the effort to combat gastric cancer progression [11, 12]. This evidence concerns the gene IL1B and gastric cancer.